$PULM
Pulmatrix, Inc.

2020 Q1 Form 10-K Financial Statement

#000119312520086168 Filed on March 26, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q4 2019 Q1
Revenue $2.760M $1.690M $0.00
YoY Change 1004.58% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.210M $1.590M $1.990M
YoY Change 11.06% 0.0% -2.93%
% of Gross Profit
Research & Development $5.290M $4.210M $2.176M
YoY Change 143.11% 30.7% -32.44%
% of Gross Profit
Depreciation & Amortization $50.00K $40.00K $50.00K
YoY Change 0.0% -20.0% -16.67%
% of Gross Profit
Operating Expenses $7.500M $5.800M $4.957M
YoY Change 51.3% 10.12% -5.89%
Operating Profit -$4.957M
YoY Change -3.07%
Interest Expense $50.00K $70.00K $0.00
YoY Change -33.96% -100.0%
% of Operating Profit
Other Income/Expense, Net $0.00 $1.000K
YoY Change -100.0% -200.0%
Pretax Income -$4.690M -$4.040M -$5.160M
YoY Change -9.11% -6.91% -1.15%
Income Tax
% Of Pretax Income
Net Earnings -$4.690M -$4.040M -$5.156M
YoY Change -9.04% -22.62% -1.24%
Net Earnings / Revenue -169.93% -239.05%
Basic Earnings Per Share
Diluted Earnings Per Share -$229.1K -$198.7K -$743.5K
COMMON SHARES
Basic Shares Outstanding 20.52M 19.99M 8.028M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q1 2019 Q4 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $24.40M $23.44M $2.150M
YoY Change 1034.88% 815.63% 38.71%
Cash & Equivalents $24.40M $23.44M $2.146M
Short-Term Investments
Other Short-Term Assets $1.850M $780.0K $1.230M
YoY Change 50.41% 8.33% 251.43%
Inventory
Prepaid Expenses
Receivables $0.00 $7.200M
Other Receivables $0.00 $0.00
Total Short-Term Assets $26.25M $31.42M $3.382M
YoY Change 676.17% 857.84% 64.81%
LONG-TERM ASSETS
Property, Plant & Equipment $790.0K $270.0K $354.0K
YoY Change 123.16% -31.47% -36.1%
Goodwill $3.577M $10.05M
YoY Change -67.02% -7.91%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $200.0K $200.0K $200.0K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $4.570M $4.681M $10.61M
YoY Change -56.92% -59.09% -9.11%
TOTAL ASSETS
Total Short-Term Assets $26.25M $31.42M $3.382M
Total Long-Term Assets $4.570M $4.681M $10.61M
Total Assets $30.82M $36.10M $13.99M
YoY Change 120.28% 145.18% 1.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.270M $600.0K $1.611M
YoY Change -21.17% -49.28% 35.15%
Accrued Expenses $4.060M $2.514M $2.184M
YoY Change 85.9% 48.23% -11.9%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $17.36M $17.20M $3.795M
YoY Change 357.44% 497.43% -38.75%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $6.530M $7.880M
YoY Change
Total Long-Term Liabilities $6.530M $7.880M $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $17.36M $17.20M $3.795M
Total Long-Term Liabilities $6.530M $7.880M $0.00
Total Liabilities $23.89M $25.08M $3.800M
YoY Change 528.68% 771.1% -38.71%
SHAREHOLDERS EQUITY
Retained Earnings -$215.2M -$199.7M
YoY Change 10.59% 11.44%
Common Stock $226.2M $209.9M
YoY Change 9.58% 12.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.940M $11.02M $10.20M
YoY Change
Total Liabilities & Shareholders Equity $30.82M $36.10M $13.99M
YoY Change 120.28% 145.18% 1.95%

Cashflow Statement

Concept 2020 Q1 2019 Q4 2019 Q1
OPERATING ACTIVITIES
Net Income -$4.690M -$4.040M -$5.156M
YoY Change -9.04% -22.62% -1.24%
Depreciation, Depletion And Amortization $50.00K $40.00K $50.00K
YoY Change 0.0% -20.0% -16.67%
Cash From Operating Activities $800.0K -$4.430M -$3.456M
YoY Change -123.15% 6.49% 10.59%
INVESTING ACTIVITIES
Capital Expenditures -$100.0K -$10.00K $10.00K
YoY Change -1100.0% 0.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$100.0K -$10.00K -$10.00K
YoY Change 900.0% 0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.500M
YoY Change 35.35%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 260.0K 10.00K 3.049M
YoY Change -91.47% -99.66% 170.3%
NET CHANGE
Cash From Operating Activities 800.0K -4.430M -3.456M
Cash From Investing Activities -100.0K -10.00K -10.00K
Cash From Financing Activities 260.0K 10.00K 3.049M
Net Change In Cash 960.0K -4.430M -417.0K
YoY Change -330.22% 257.26% -79.12%
FREE CASH FLOW
Cash From Operating Activities $800.0K -$4.430M -$3.456M
Capital Expenditures -$100.0K -$10.00K $10.00K
Free Cash Flow $900.0K -$4.420M -$3.466M
YoY Change -125.97% 6.51%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23440000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2563000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
777000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
717000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
31417000
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
204000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
204000
CY2019Q4 us-gaap Goodwill
Goodwill
3577000
CY2018Q4 us-gaap Goodwill
Goodwill
10845000
CY2019Q4 us-gaap Assets
Assets
36098000
CY2018Q4 us-gaap Assets
Assets
14723000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
3280000
CY2019Q4 us-gaap Liabilities
Liabilities
25079000
CY2018Q4 us-gaap Liabilities
Liabilities
2879000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
36098000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14723000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
600000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1183000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2514000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1696000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17200000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2879000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
226178000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
206409000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-215161000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-194565000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
11019000
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
13411000
CY2019Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
7879000
CY2018Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0
CY2018Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
0
CY2019 us-gaap Revenues
Revenues
7910000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-20692000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-20400000
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.23
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.98
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
16733909
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4126393
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12845000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12966000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8489000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7518000
CY2019 us-gaap Operating Expenses
OperatingExpenses
28602000
CY2018 us-gaap Operating Expenses
OperatingExpenses
20553000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-20596000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-20563000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
11844000
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
17545000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2066000
CY2019 pulm Stock Issued During The Period Value Exercise Of Prefund Warrants
StockIssuedDuringThePeriodValueExerciseOfPrefundWarrants
160000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2973000
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
19219000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
182000
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
231000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
2066000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
2973000
CY2018 pulm Non Cash Interest Expenses
NonCashInterestExpenses
35000
CY2018 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
3000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
60000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
21000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-583000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
726000
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
885000
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-221000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3230000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16761000
CY2019 pulm Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
17545000
CY2018 pulm Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
19297000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
17705000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15793000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2767000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3754000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23644000
CY2018 pulm Fair Value Adjustment On Derivative Liability
FairValueAdjustmentOnDerivativeLiability
-1000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
20877000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-987000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
58000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
19000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-58000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-19000
CY2018 pulm End Of Term Loan Payments
EndOfTermLoanPayments
-245000
CY2018 us-gaap Proceeds From Repayments Of Debt
ProceedsFromRepaymentsOfDebt
-3259000
CY2019 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
160000
CY2019 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
21290000
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
204000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
204000
CY2019Q4 us-gaap Prepaid Insurance
PrepaidInsurance
202000
CY2019Q4 pulm Prepaid Clinical Trials
PrepaidClinicalTrials
322000
CY2019Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
221000
CY2019Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
32000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2555000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2285000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
270000
CY2019 us-gaap Depreciation And Amortization
DepreciationAndAmortization
182000
CY2018 us-gaap Depreciation And Amortization
DepreciationAndAmortization
231000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
40000
CY2019Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
42000
CY2019Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
527000
CY2019Q4 pulm Accrued Legal And Patent Current
AccruedLegalAndPatentCurrent
85000
CY2019Q4 pulm Accrued Clinical And Consulting Current
AccruedClinicalAndConsultingCurrent
1820000
CY2019Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.125
CY2019Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
1706484
CY2019Q1 us-gaap Share Price
SharePrice
1.465
CY2019Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.8313
CY2019Q1 pulm Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
110922
CY2019Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2500000
CY2019Q3 pulm Class Of Warrant Or Right Fair Value Per Warrant
ClassOfWarrantOrRightFairValuePerWarrant
0.005314
CY2019Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
797334
CY2018Q2 pulm Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
15000
CY2019Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
7.50
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
972569
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
651600
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.06
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
724166
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
18.54
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
900003
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.63
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
401453
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y8M15D
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
23.14
CY2019 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y10M17D
CY2019Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
746000
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
2066000
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
2973000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
698000
CY2019 dei Document Type
DocumentType
10-K
CY2019 dei Document Period End Date
DocumentPeriodEndDate
2019-12-31
CY2019 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2019 dei Entity Central Index Key
EntityCentralIndexKey
0001574235
CY2019 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2019 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2019 dei Trading Symbol
TradingSymbol
PULM
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7200000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
630000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
675000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19994560
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4923723
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4923723
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19994560
CY2018 us-gaap Revenues
Revenues
153000
CY2019 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
7268000
CY2018 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
69000
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
96000
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-163000
CY2019Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1280000
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1213000
CY2018 us-gaap Interest Expense
InterestExpense
186000
CY2018 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1000
CY2019 us-gaap Investment Income Interest
InvestmentIncomeInterest
301000
CY2018 us-gaap Investment Income Interest
InvestmentIncomeInterest
27000
CY2019 pulm Other Nonoperating Settlement Charge
OtherNonoperatingSettlementCharge
200000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000
CY2019Q4 us-gaap Deposits Money Market Deposits
DepositsMoneyMarketDeposits
51000
CY2019 pulm Cash Restricted For Letter Of Credit
CashRestrictedForLetterOfCredit
153000
CY2018Q4 us-gaap Prepaid Insurance
PrepaidInsurance
243000
CY2018Q4 pulm Prepaid Clinical Trials
PrepaidClinicalTrials
419000
CY2018Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
27000
CY2018Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
28000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2510000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2116000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
394000
CY2019Q4 us-gaap Disposal Group Including Discontinued Operation Property Plant And Equipment
DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
13000
CY2018Q4 us-gaap Disposal Group Including Discontinued Operation Property Plant And Equipment
DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
993000
CY2019 us-gaap Depreciation And Amortization Discontinued Operations
DepreciationAndAmortizationDiscontinuedOperations
13000
CY2018 us-gaap Depreciation And Amortization Discontinued Operations
DepreciationAndAmortizationDiscontinuedOperations
985000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
10137000
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19553198
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4703517
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.039
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.062
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.020
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.019
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.073
CY2019 pulm Effective Income Tax Reconciliation Limitations On Credit And Net Operating Losses
EffectiveIncomeTaxReconciliationLimitationsOnCreditAndNetOperatingLosses
-1.713
CY2018 pulm Effective Income Tax Reconciliation Limitations On Credit And Net Operating Losses
EffectiveIncomeTaxReconciliationLimitationsOnCreditAndNetOperatingLosses
0.000
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.014
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.003
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
1.611
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.282
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2019Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
9077000
CY2018Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
37640000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
382000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3170000
CY2019Q4 pulm Deferred Tax Assets Deferred Expense Capitalized Startup
DeferredTaxAssetsDeferredExpenseCapitalizedStartup
711000
CY2018Q4 pulm Deferred Tax Assets Deferred Expense Capitalized Startup
DeferredTaxAssetsDeferredExpenseCapitalizedStartup
851000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1031000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2589000
CY2019Q4 pulm Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
184000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
382000
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
520000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
11767000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
44770000
CY2019Q4 pulm Deferred Tax Liability Right Of Use Asset
DeferredTaxLiabilityRightOfUseAsset
172000
CY2019Q4 us-gaap Operating Loss Carryforwards Valuation Allowance
OperatingLossCarryforwardsValuationAllowance
11595000
CY2018Q4 us-gaap Operating Loss Carryforwards Valuation Allowance
OperatingLossCarryforwardsValuationAllowance
44770000
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1109000
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
115000
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
20000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1244000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
87000
CY2019 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
1244000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
87000
CY2019Q2 pulm Class Of Warrant Or Right Fair Value Per Warrant
ClassOfWarrantOrRightFairValuePerWarrant
0.012632
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
37602000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
18674000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P2Y5M8D
CY2017Q4 pulm Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAggregateIntrinsicValue
0
CY2018 pulm Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Issued Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageExercisePrice
10.78
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P4Y3M18D
CY2018Q4 pulm Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAggregateIntrinsicValue
0
CY2019Q4 pulm Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAggregateIntrinsicValue
0
CY2019 pulm Amortization Of Operating Lease Rightofuse Asset
AmortizationOfOperatingLeaseRightofuseAsset
583000
CY2018 us-gaap Interest Paid Net
InterestPaidNet
131000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1213000
CY2019 pulm Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-605000
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
33175000
CY2019 pulm Deferred Tax Assets Tax Credit Carryforwards Expiration Date Description
DeferredTaxAssetsTaxCreditCarryforwardsExpirationDateDescription
various dates from 2022 through 2039.
CY2019 pulm Operating Loss Carryforwards Expiration Date Description
OperatingLossCarryforwardsExpirationDateDescription
various dates from 2023 through 2039
CY2018 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-8000
CY2019 us-gaap Profit Loss
ProfitLoss
-20596000
CY2018 us-gaap Profit Loss
ProfitLoss
-20563000
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
18953195
CY2018Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
59000
CY2018Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
915000
CY2019 pulm Effective Income Tax Rate Reconciliation Writedown Of Godwill Percent
EffectiveIncomeTaxRateReconciliationWritedownOfGodwillPercent
-0.074
CY2019 pulm Effective Income Tax Rate Reconciliation Nondeductible Expense Permanent Differences
EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferences
-0.006
CY2018 pulm Effective Income Tax Rate Reconciliation Nondeductible Expense Permanent Differences
EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferences
-0.005
CY2018Q4 pulm Accrued Clinical And Consulting Current
AccruedClinicalAndConsultingCurrent
517000
CY2018Q4 pulm Accrued Legal And Patent Current
AccruedLegalAndPatentCurrent
67000
CY2018Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
67000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
71000
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0744
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
676000
CY2019 us-gaap Variable Lease Cost
VariableLeaseCost
CY2019Q4 pulm Total Lease Assets
TotalLeaseAssets
630000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
698000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
698000
CY2019Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
23000
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
675000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2019Q4 pulm Total Deferred Tax Liabilities
TotalDeferredTaxLiabilities
172000
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
654000
CY2019 us-gaap Lease Cost
LeaseCost
654000
CY2019 pulm Classofwarrantorrightexercised
Classofwarrantorrightexercised
8647112
CY2018Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4428444
CY2019 dei Entity Registrant Name
EntityRegistrantName
Pulmatrix, Inc.
CY2019 dei Amendment Flag
AmendmentFlag
false
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019 dei Entity Small Business
EntitySmallBusiness
true
CY2019Q2 dei Entity Public Float
EntityPublicFloat
17267361
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20521304
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2018 pulm Cash Restricted For Letter Of Credit
CashRestrictedForLetterOfCredit
153000
CY2019 us-gaap Asset Impairment Charges
AssetImpairmentCharges
7268000
CY2018 us-gaap Asset Impairment Charges
AssetImpairmentCharges
69000
CY2019Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-10
CY2019 us-gaap Short Term Lease Cost
ShortTermLeaseCost
5000
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.000
CY2018 pulm Effective Income Tax Rate Reconciliation Writedown Of Godwill Percent
EffectiveIncomeTaxRateReconciliationWritedownOfGodwillPercent
-0.001
CY2019Q4 pulm Percentage Of Net Operating Losses Utilization
PercentageOfNetOperatingLossesUtilization
0.80
CY2018 pulm Stock Issued During The Period Value Exercise Of Prefund Warrants
StockIssuedDuringThePeriodValueExerciseOfPrefundWarrants
78000
CY2019 dei Entity Address State Or Province
EntityAddressStateOrProvince
DE
CY2019 dei Security12b Title
Security12bTitle
Common Stock
CY2019 dei Entity Address Country
EntityAddressCountry
MA
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
23.85
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7200000
CY2018Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
697500
CY2018Q4 us-gaap Share Price
SharePrice
3.10
CY2018Q4 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
2162000
CY2019Q4 pulm Class Of Warrant Or Right Exercised Per Share
ClassOfWarrantOrRightExercisedPerShare
3.90
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
676000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1374000
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y5M15D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M7D
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Use of Estimates </div></div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In preparing consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results may differ from these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payments, estimating the useful lives of depreciable and amortizable assets, <div style="letter-spacing: 0px; top: 0px;;display:inline;">interest borrowing rate, </div>valuation allowance against deferred tax assets, goodwill impairment, and estimating the fair value of long-lived assets to assess whether impairment charges may apply. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

Files In Submission

Name View Source Status
0001193125-20-086168-index-headers.html Edgar Link pending
0001193125-20-086168-index.html Edgar Link pending
0001193125-20-086168.txt Edgar Link pending
0001193125-20-086168-xbrl.zip Edgar Link pending
d862269d10k.htm Edgar Link pending
d862269dex1013.htm Edgar Link pending
d862269dex231.htm Edgar Link pending
d862269dex311.htm Edgar Link pending
d862269dex312.htm Edgar Link pending
d862269dex321.htm Edgar Link pending
d862269dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g862269g0316231137146.jpg Edgar Link pending
g862269page049a.jpg Edgar Link pending
g862269page049b.jpg Edgar Link pending
g862269page050.jpg Edgar Link pending
g862269page051.jpg Edgar Link pending
g862269page052.jpg Edgar Link pending
g862269page053.jpg Edgar Link pending
pulm-20191231.xml Edgar Link completed
pulm-20191231.xsd Edgar Link pending
pulm-20191231_cal.xml Edgar Link unprocessable
pulm-20191231_def.xml Edgar Link unprocessable
pulm-20191231_lab.xml Edgar Link unprocessable
pulm-20191231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending